(Q36488717)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16723985%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

review article

1 reference

title

Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16723985%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16723985%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Zoccali C

series ordinal

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

24 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16723985%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16723985%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16723985%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16723985%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

26-33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16723985%20AND%20SRC:MED&resulttype=core&format=json

A general cardiovascular risk profile: The Framingham study

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Prevalence and Correlates of Elevated Serum Creatinine Levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Predictors of new-onset kidney disease in a community-based population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Screening for chronic kidney disease: unresolved issues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Cardiovascular disease risk factors in chronic renal insufficiency.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Traditional and emerging cardiovascular risk factors in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Oxidative stress in end-stage renal disease: an emerging threat to patient outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Subtle acquired renal injury as a mechanism of salt-sensitive hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Pathogenesis of vascular calcification in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

The association of interdialytic weight gain with nutritional parameters and mortality risk in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

C-reactive protein is associated with renal function abnormalities in a non-diabetic population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Effect of pravastatin on cardiovascular events in people with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Monocyte/macrophage regulation of vascular calcification in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Cardiac Valve Calcification as an Important Predictor for All-Cause Mortality and Cardiovascular Mortality in Long-Term Peritoneal Dialysis Patients: A Prospective Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Sympathetic nerve activity in obstructive sleep apnoea

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Norepinephrine and concentric hypertrophy in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Endothelial dysfunction and mild renal insufficiency in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension : modulation of nitric oxide synthesis by salt intake

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

The role of nitric oxide in hypertension and renal disease progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

The metabolic syndrome and chronic kidney disease in U.S. adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

The CREATE trial--building the evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021

Shattuck lecture--clinical research to clinical practice--lost in translation?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000417

7 January 2021